Friday Jul 4 | Medical News Today
Relapse Time Prolonged In Clinically Stable Patients With Bipolar I...
Main Category: Bipolar Also Included In: Psychology / Psychiatry ; Clinical Trials / Drug Trials Article Date: 04 Jul 2008 - 0:00 PDT printer friendly view / write opinions rate article AstraZeneca announced ...
US court rulings helps AstraZeneca stave-off Teva, Sandoz over 4$-billion Seroquel
The New Jersey District Court has upheld upheld Anglo-Swedish pharmaceutical group AstraZeneca's patent rights to the schizophrenia and bipolar blockbuster Seroquel, which yields it over $4 billion a year.
AstraZeneca wins legal round in Teva Seroquel row
Teva Pharmaceutical Industries Ltd said on Tuesday that AstraZeneca Plc won the latest court battle in their patent dispute over a generic version of AstraZeneca's blockbuster schizophrenia drug.
Ontario Becomes Second Province to Cover New Treatment for Patients...
Ontarians with schizophrenia have renewed hope for a better life following the Ontario Government's decision to expand treatment options for patients through the listing of SEROQUEL XR on the provincial ...
AstraZeneca Submits Seroquel XR in Europe for the Treatment of Major Depressive Disorder
AstraZeneca today announced that the company has submitted applications in the European Union for once-daily SEROQUEL XR Extended-Release Tablets , seeking approval for the treatment of major depressive ...
Antipsychotic Drugs Appear to be Potential Killers for Senior Citizens with Dementia
Older adults with dementia who receive short-term treatment with antipsychotic medications are more likely to be hospitalized or die than those who do not take the drugs, according to a report in the May 26 ...
Thought Leader Insight & Analysis: Anxiety & Depression Provides an...
May 22, 2008 - Research and Markets has announced the addition of "Thought Leader Insight & Analysis: Anxiety & Depression" to their offering.
FDA Approves Astrazeneca's Seroquel For Maintenance Treatment In Bipolar Disorder
Main Category: Bipolar Also Included In: Regulatory Affairs / Drug Approvals ; Psychology / Psychiatry Article Date: 16 May 2008 - 2:00 PDT AstraZeneca announced that the U.S. Food and Drug Administration has ... via Medical News Today
FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder
“To date, long-term controlled studies of maintenance therapies have been relatively few and typically focused on either the manic or depressive phase of the illness, but not on both”
SEROQUEL is approved by the FDA for the treatment of schizophrenia, and is also the only single agent approved by the FDA for the treatment of both depressive episodes in bipolar disorder and acute manic ... via Earth Times
Risperidone Long-Acting Injection Extends Time To Relapse in Schizophrenia
In a study comparing the time it takes for someone with schizophrenia to relapse , risperidone long-acting injection was found to offer a longer time before relapse than another commonly prescribed ... via Psych Central News
Seroquel Evaluation On Improvement In Short And Long-Term Symptoms
In a six-week, multicenter, double-blind study, 723 patients were randomized to receive quetiapine XR 50mg/day, 150mg/day or 300mg/day, or placebo. via Medical News Today
New Data on Seroquel XR in Treatment of Both Major Depressive...
“New MDD therapy options are clearly needed. Studies have shown that at least one-third of MDD patients who are treated with antidepressants fail to achieve a satisfactory response”
AstraZeneca today announced new study data on SEROQUEL XR Extended-Release Tablets for the treatment of major depressive disorder and generalized anxiety disorder in adult patients. via Med Ad News
AstraZeneca Announces First Presentation Of Pivotal Seroquel XR(TM) Bipolar Studies
Main Category: Bipolar Also Included In: Psychology / Psychiatry ; Mental Health ; Depression Article Date: 15 Apr 2008 - 1:00 PDT New pivotal trial data from two clinical studies with SEROQUEL XR once daily ... via Medical News Today
Bipolar Depression Licence Application For Seroquel
Main Category: Bipolar Also Included In: Regulatory Affairs / Drug Approvals ; Schizophrenia Article Date: 18 Feb 2008 - 1:00 PST newsletters AstraZeneca has submitted an application to the Medicines and ... via Medical News Today
AstraZeneca Submits Seroquel XR in Europe for the Treatment of...
AstraZeneca today announced that the company has submitted applications in the European Union under the Mutual Recognition Procedure for once-daily SEROQUEL XRTM Extended-Release Tablets, seeking approval for ... via Med Ad News
How Toxic is Britney's Pill Popping?
“Drugs have very different ways of getting into the bloodstream when you crush them up. Nobody should be messing with drugs without a physician's supervision.”
The combination of prescription drugs that Britney Spears' mother claims were ground up in the singer's food was a risky mix that could cause hysterical outbursts, agitation, creepy hallucinations, even a ... via ABC News
New Analysis Demonstrates Efficacy Of Seroquel (Quetiapine Fumarate)...
“Our analysis of data from more than a thousand patients suggest the potential of treatment regimens which include Seroquel along with a mood stabiliser to reduce the likelihood of mood events.”
Main Category: Bipolar Also Included In: Clinical Trials / Drug Trials Article Date: 30 Jan 2008 - 16:00 PST newsletters Results from a combined analysis of two long term phase III clinical trials2,3 have shown ... via Medical News Today
How does Seroquel work? What will it do for me? Quetiapine belongs to the class of medications known as antipsychotics . via Calgary Herald
AstraZeneca Submits sNDAs for Seroquel XR for the Treatment of Bipolar Mania and Bipolar Depression
AstraZeneca today announced that the company has submitted two separate supplemental New Drug Applications to the U.S. Food and Drug Administration for once-daily SEROQUEL XRTM Extended-Release Tablets to seek ... via Med Ad News
Mental Health Year in Review: 2007
“There were no differences in measures of effectiveness between initiation of active treatments or placebo (which represented watchful waiting) b ut the placebo group had significantly lower health care costs. [Ed. - emphasis added]”
No significant breakthroughs in our understanding of any particular mental disorder occurred in 2007, although new techniques, such as functional magnetic resonance imaging and genetic studies continue to be at ... via World of Psychology